First-line vascular endothelial growth factor inhibitors for advanced renal cell carcinoma and the impact of new agents entering the treatment paradigm

BJU Int. 2017 Dec;120(6):749-751. doi: 10.1111/bju.13954. Epub 2017 Jul 30.

Authors

Rohit Jain¹, Saby George¹

Affiliation

¹ Roswell Park Institute, Buffalo, NY, USA.

PMID: 28688143
DOI: 10.1111/bju.13954

No abstract available

Publication types

Letter
Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / mortality
Carcinoma, Renal Cell / pathology*
Disease-Free Survival
Female
Humans
Male
Neoplasm Invasiveness / pathology
Neoplasm Staging
Prognosis
Protein Kinase Inhibitors / administration & dosage*
Randomized Controlled Trials as Topic
Receptors, Vascular Endothelial Growth Factor / administration & dosage
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
Risk Assessment
Survival Rate
Treatment Outcome

Substances

Protein Kinase Inhibitors
Receptors, Vascular Endothelial Growth Factor